WEBULL
WebtradeDownload

Immatics (IMTX) Stock Dropped, So What Is Driving Attention Now?

Simply Wall St · 2d ago

Conference spotlight and why it matters for Immatics stock

Immatics (NasdaqCM:IMTX) stepped into the scientific spotlight at the 25th Human Proteome Organization World Congress in Singapore, highlighting its HybridDIA approach to quantitative immunopeptidomics and drawing fresh attention to the stock.

Recent trading has been rough for Immatics. The share price has slipped to US$7.50, with the 7 day share price return down 14.6% and the 30 day share price return down 21.6%, while the 1 year total shareholder return has declined 27.7%. This points to fading momentum even as the HUPO presentations remind the market of the company’s research pipeline and may gradually reshape how investors weigh its growth potential against perceived risks.

Scan beyond Immatics and look for other research driven biotechs that may be positioned for a rebound using our curated list of 34 healthcare AI stocks.

Immatics is advancing its work in the lab even as the share price has declined significantly in recent months. Does that mismatch signal opportunity, or is the stock simply reflecting the risks on the table today?

Preferred price-to-sales of 21.8x for Immatics: Is it justified?

On recent pricing, Immatics trades on a P/S ratio of 21.8x, which places a rich tag on a stock that has fallen sharply over the past year while remaining loss making.

P/S compares the company’s market value to its revenue and is often used for early stage biotechs where earnings are still negative. For Immatics, investors are effectively paying a high multiple of the current US$41.7m revenue base to access its T cell focused oncology pipeline and existing collaboration agreements.

That price tag comes with tension. The business is forecast to grow revenue at 50.8% per year and faster than the wider US market. However, it is expected to stay unprofitable over the next three years and has reported losses that have increased at 19.9% per year over the past five years. The market is pricing the shares above both the estimated fair P/S of 0x and the peer and industry averages, which points to expectations that are already demanding.

Relative comparisons look even tougher. Immatics trades on a 21.8x P/S compared with 12.7x for the broader US biotech group and 12.6x for its peer set. As a result, the stock carries a heavy premium that could compress if sentiment toward high risk funding structures and continued losses weakens.

Explore the SWS fair ratio for Immatics.

Result: Price-to-sales of 21.8x (OVERVALUED)

Still, the clinical trial track for Immatics and the reliance on partners like Moderna and Genmab could quickly challenge today’s premium P/S story.

Find out about the key risks to this Immatics narrative.

Next Steps

Conflicted about whether the recent drop in Immatics reflects real risk or just short term nerves, especially with both concerns and potential upsides in play? Act quickly, review the underlying numbers, and stress test the story from both angles by checking the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Immatics?

Do not stop at Immatics. Use the Simply Wall St screener to widen your watchlist and pressure test where your next dollar really works hardest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.